12
MAY
2021

UK Manufacturing Facility & Phase III Trial Updates From Northwest Biotherapeutics (OTCQB: NWBO)

Posted By :
Comments : Off
FOR IMMEDIATE RELEASE CONTACTS Dave Innes 804-513-4758 dinnes@nwbio.com Les Goldman 240-234-0059 lgoldman@nwbio.com Application Submitted to MHRA for Certification of Sawston Facility BETHESDA, Md., May 12, 2021 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that an application for certification of the manufacturing...
Read More
16
MAR
2021

Northwest Biotherapeutics Announces Development Completed for Initial Production Capacity of Sawston, UK Facility

Posted By :
Comments : Off
FOR IMMEDIATE RELEASE CONTACTS Dave Innes 804-513-4758 dinnes@nwbio.com Les Goldman 240-234-0059 lgoldman@nwbio.com Northwest Biotherapeutics Announces Development Completed for Initial Production Capacity of Sawston, UK Facility Application for MHRA Regulatory Certification of Facility In Preparation BETHESDA, Md., March 16, 2021 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax®...
Read More
05
OCT
2020

Northwest Biotherapeutics Announces Data Lock of Phase III Trial

Posted By :
Comments : Off
FOR IMMEDIATE RELEASE CONTACTS Dave Innes 804-513-4758 dinnes@nwbio.com Les Goldman 240-234-0059 lgoldman@nwbio.com BETHESDA, Md., October 5, 2020 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the database for the Phase III trial of DCVax®-L for Gliobastoma has been locked. With the database now locked, the...
Read More
01
SEP
2020

Northwest Biotherapeutics Acquires Flaskworks: Breakthrough Automation Technology For Cell Therapy Products To Enable Scale-Up of Production Volumes and Reduction of Production Costs

Posted By :
Comments : Off
BETHESDA, Md., September 1, 2020 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the Company has acquired Flaskworks, a company that has developed a breakthrough system to close and automate the manufacturing of cell therapy products such as DCVax®. Flaskworks was previously owned by its technical founders and...
Read More
27
AUG
2020

NW Bio Accelerating Sawston Plant Phase I Buildout: Construction Crews Working Double Shifts To Accelerate Completion Despite COVID Effects

Posted By :
Comments : Off
BETHESDA, Md., August 27, 2020 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the Company is pursuing an intensive program of manufacturing preparations and planning as the Company approaches top line data from its Phase III trial of DCVax®-L.  A cornerstone of this expanding program is completion of the Phase I...
Read More